Elliott S Klein from 20 Winton Farm Rd, Newtown, CT 06470, age 67, Phone: 2032700643

Us Patents

Synthesis And Use Of Retinoid Compounds Having Negative Hormone And/Or Anatgonist Activities
view source
US Patent:

6469028, Oct 22, 2002
Filed:

Mar 28, 2001
Appl. No.:

09/821673
Inventors:

Elliott S. Klein - Marina del Rey CA
Alan T. Johnson - Rancho Santa Margarita CA
Andrew M. Standeven - Corona del Mar CA
Richard L. Beard - Newport Beach CA
Samuel J. Gillett - Albany CA
Tien T. Duong - Irvine CA
Sunil Nagpal - Lake Forest CA
Vidyasagar Vuligonda - Irvine CA
Min Teng - Aliso Viejo CA
Roshantha A. Chandraratna - Mission Viejo CA
Assignee:

Allergan, Inc. - Irvine CA
International Classification:

C07D21514
US Classification:

514311, 514314, 514432, 514456, 546167, 546168, 549 23, 549362
Abstract:

Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity.

Male Anti-Fertility Agents
view source
US Patent:

6521641, Feb 18, 2003
Filed:

Jun 9, 2000
Appl. No.:

09/591253
Inventors:

Elliott S. Klein - Marina Del Rey CA
Yang-Dar Yuan - Irvine CA
Roshantha A. Chandraratna - Laguna Hills CA
Assignee:

Allergan, Inc. - Irvine CA
International Classification:

A61P 1516
US Classification:

514333, 514332, 514337, 514456, 514841, 514454, 514437, 514432, 514411, 514412, 514438, 514468
Abstract:

Methods and compositions for inhibiting or preventing spermatogenesis in a male mammal. Also disclosed are compounds and formulations for use in such methods.

Identification Of Nuclear Receptor-Dependent Coregulator Recruitment
view source
US Patent:

20020037514, Mar 28, 2002
Filed:

Mar 22, 2001
Appl. No.:

09/815156
Inventors:

Elliott Klein - Danbury CT, US
Weizhen Wang - Newport Coast CA, US
Roshantha Chandraratna - Laguna Hills CA, US
International Classification:

C12Q001/68
US Classification:

435/006000
Abstract:

Methods for identifying molecules that modulate nuclear receptor transactivation activity. Also disclosed are methods for detecting endogenous nuclear receptor co-factors with increased sensitivity.

Methods Of Treating Hyperlipidemia
view source
US Patent:

20020193403, Dec 19, 2002
Filed:

May 3, 2001
Appl. No.:

09/848159
Inventors:

Yang-Dar Yuan - Irvine CA, US
Scott Thacher - Costa Mesa CA, US
Elliott Klein - Danbury CT, US
Roshantha Chandraratna - Laguna Hills CA, US
Assignee:

Allergan Sales, Inc. - Irvine CA
International Classification:

A61K031/47
A61K031/353
A61K031/38
US Classification:

514/311000, 514/432000, 514/456000
Abstract:

The current invention relates to methods for treating hyperlipidemia in mammals, including humans. More specifically, the current invention relates to the use of retinoid or retinoid derivative that is able to act as an antagonist or inverse agonist of a retinoid receptor to treat hyperlipidemia.

Methods Of Detecting Dissociated Nuclear Hormone Receptor Ligands
view source
US Patent:

20030003517, Jan 2, 2003
Filed:

Mar 22, 2001
Appl. No.:

09/814604
Inventors:

Elliott Klein - Danbury CT, US
Weizhen Wang - Newport Coast CA, US
Roshantha Chandraratna - Laguna Hills CA, US
International Classification:

G01N033/567
US Classification:

435/007210
Abstract:

The present invention provides a method of identifying an effective agent that dissociates nuclear hormone receptor activities. The method includes the steps of contacting a nuclear hormone receptor with one or more agents under conditions suitable for forming a test complex containing nuclear hormone receptor dimer, coactivator and corepressor; assaying for coactivator association with the test complex; and assaying for corepressor association with the test complex, where coactivator association combined with corepressor association indicates that at least one of the agents is an effective agent that dissociates nuclear hormone receptor activities.

Male Anti-Fertility Agents
view source
US Patent:

20030144256, Jul 31, 2003
Filed:

Nov 25, 2002
Appl. No.:

10/304665
Inventors:

Elliott Klein - Marina Del Rey CA, US
Yang-Dar Yuan - Irvine CA, US
Roshantha Chandraratna - Laguna Hills CA, US
Assignee:

Allergan Sales, Inc.
International Classification:

A61K031/695
A61K031/655
A61K031/506
A61K031/501
A61K031/497
A61K031/4709
A61K031/47
A61K031/4436
A61K031/427
A61K031/422
A61K031/4178
A61K031/416
A61K031/382
A61K031/353
US Classification:

514/150000, 514/311000, 514/456000, 514/432000, 514/252010, 514/252030, 514/252040, 514/255050, 514/256000, 514/365000, 514/372000, 514/397000, 514/314000, 514/063000, 514/337000, 514/406000
Abstract:

Methods and compositions for inhibiting or preventing spermatogenesis in a male mammal. Also disclosed are compounds and formulations for use in such methods.

Synthesis And Use Of Retinoid Compounds Having Negative Hormone And/Or Antagonist Activities
view source
US Patent:

20030219832, Nov 27, 2003
Filed:

May 27, 2003
Appl. No.:

10/446580
Inventors:

Elliott Klein - Marina Del Rey CA, US
Andrew Standeven - Ventura CA, US
Sunil Nagpal - Lake Forest CA, US
Roshantha Chandraratna - Mission Viejo CA, US
International Classification:

G01N033/53
A61K031/59
A61K031/455
A61K031/192
A61K031/203
A61K031/195
US Classification:

435/007100, 514/557000, 514/559000, 514/355000, 514/567000, 514/569000, 514/167000
Abstract:

Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.

Methods Of Treating Hyperlipidemia
view source
US Patent:

20050171151, Aug 4, 2005
Filed:

Dec 17, 2004
Appl. No.:

11/016534
Inventors:

Yang-Dar Yuan - Irvine CA, US
Scott Thacher - Costa Mesa CA, US
Elliott Klein - Danbury CT, US
Roshantha Chandraratna - Laguna Hills CA, US
Assignee:

Allergan, Inc. - Irvine CA
International Classification:

A61K031/47
A61K031/382
A61K031/353
US Classification:

514312000, 514456000, 514432000
Abstract:

The current invention relates to methods for treating hyperlipidemia in mammals, including humans. More specifically, the current invention relates to the use of retinoid or retinoid derivative that is able to act as an antagonist or inverse agonist of a retinoid receptor to treat hyperlipidemia.

Name / Title

Company / Classification

Phones & Addresses

Elliott Klein
S

COAST MORTGAGE CORP
Loan Broker

PO Box 7817, Beverly Hills, CA 90212

Lawyers & Attorneys

Elliott Warren Klein - Lawyer

view source

Licenses:

New York - Currently registered 1979

Education:

State University of New York at Buffalo

Elliott Klein - Lawyer

view source

Specialties:

Workers Compensation
Employer Liability
Products Liability
General Liability Defense
Subrogation
Administrative and Public
Oil & Gas
Insurance
Labor-Employment
Environmental and Natural Resources
Litigation: Personal Injury

ISLN:

905839064

Admitted:

1979

University:

State University of New York at Buffalo, B.A., 1975

Law School:

State University of New York at Buffalo, J.D., 1978